316 related articles for article (PubMed ID: 34511582)
1. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
3. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Shimada S; Eladl AE; Elsayed AA; Daroontum T; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
Pathol Int; 2020 Aug; 70(8):481-492. PubMed ID: 32367595
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
5. EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency.
Satou A; Nakamura S
Cancer Med; 2021 Oct; 10(19):6777-6785. PubMed ID: 34387382
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases.
Sakakibara A; Kohno K; Iwakoshi A; Moritani S; Fujishiro A; Kito K; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Takahashi E; Ohashi A; Satou A; Kato S; Asano N; Nakamura S
Pathol Int; 2020 Feb; 70(2):116-122. PubMed ID: 31894883
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type.
Kohno K; Suzuki Y; Elsayed AA; Sakakibara A; Takahara T; Satou A; Kato S; Nakamura S; Asano N
Am J Clin Pathol; 2020 Apr; 153(5):571-582. PubMed ID: 31977037
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
[TBL] [Abstract][Full Text] [Related]
11. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological analysis of neoplastic PD-L1-positive EBV
Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
[TBL] [Abstract][Full Text] [Related]
13. Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry.
Kohno K; Sakakibara A; Iwakoshi A; Hasegawa M; Adachi S; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Takahashi E; Ohashi A; Satou A; Kato S; Asano N; Nakamura S
Pathol Int; 2020 Feb; 70(2):108-115. PubMed ID: 31894892
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
15. PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
Volaric A; Bacchi CE; Gru AA
Am J Surg Pathol; 2020 Oct; 44(10):1353-1366. PubMed ID: 32649320
[TBL] [Abstract][Full Text] [Related]
16. Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases.
Takahashi E; Imai H; Tsuyuki Y; Taniguchi N; Kogure Y; Kataoka K; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Nakamura S
J Clin Exp Hematop; 2023; 63(1):49-57. PubMed ID: 36990776
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.
Suzuki Y; Kohno K; Matsue K; Sakakibara A; Ishikawa E; Shimada S; Shimada K; Mabuchi S; Takahara T; Kato S; Nakamura S; Satou A
Cancer Med; 2020 Jul; 9(13):4768-4776. PubMed ID: 32367674
[TBL] [Abstract][Full Text] [Related]
18. Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
Suzuki Y; Sakakibara A; Shimada K; Shimada S; Ishikawa E; Nakamura S; Kato S; Takahara T; Asano N; Satou A; Kohno K
Pathol Int; 2019 Jan; 69(1):13-20. PubMed ID: 30601579
[TBL] [Abstract][Full Text] [Related]
19. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
20. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
